FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085115221> ?p ?o ?g. }

• W2085115221 endingPage "1189" @default.
• W2085115221 startingPage "1181" @default.
• W2085115221 abstract "Abstract We examined the effect of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, and N-(9-fluorenyl-methyloxycarbonyl)-l-leucine (F-l-Leu), a peroxisome proliferator-activated receptor γ (PPARγ) agonist, separately and combined, on the development of methylnitrosourea (MNU)-induced rat mammary gland carcinogenesis. Celecoxib and F-l-Leu significantly reduced tumor incidence and multiplicity (P &lt; 0.05). Combining both agents exerted higher (synergistic) cancer inhibition than separate treatments (P &lt; 0.05). The effects of the test drugs on COX-2 and PPARγ expression and on the synthesis of prostaglandin E2 (PGE2) and 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) were examined in rat mammary normal (MNU-untreated), uninvolved, and tumor (MNU-treated) tissues. Celecoxib and F-l-Leu, separately, inhibited COX-2 and up-regulated PPARγ expression. These effects were paralleled by inhibition of PGE2 synthesis and up-regulation of 15d-PGJ2. Combined treatment resulted in higher alterations in COX-2 and PPARγ transcripts and PG synthesis compared with separate administrations. The effect of the test agents on Bcl2, BAX, and protein kinase Cα expression levels were examined in the rat mammary gland and the pro-(BAX:Bcl2) and anti-[PKCα*(Bcl2/BAX)] apoptotic ratios were evaluated. Each drug increased the proapoptotic ratio by 2- to 7-fold and reduced the antiapoptotic ratio by 2- to &gt;8-fold in all tissues. Combined treatment, however, resulted in &gt;9- to 14-fold up-regulation in the proapoptotic processes and 15- to &gt;30-fold down-regulation in the antiapoptotic ones. Analyses were also carried out on the drug-induced modulation of cell cycle regulators and proliferation markers (cyclin-dependent kinase 1 and proliferating cell nuclear antigen). F-l-Leu and celecoxib each reduced the cyclin-dependent kinase 1 and proliferating cell nuclear antigen expression in the tumor. Higher down-regulation was attained in all tissues by combined treatment where cyclin-dependent kinase 1 and proliferating cell nuclear antigen almost retained the expression levels observed in the normal glands. In conclusion, simultaneous targeting of COX-2 and PPARγ may inhibit mammary cancer development more effectively than targeting each molecule alone. COX-2 inhibitors and PPARγ agonists coordinately mediate their anticancer effect via both COX-dependent (inhibition of COX-2, activation of PPARγ, and modulation PG synthesis) and COX-independent (induction of proapoptotic factors and inhibition of cell proliferation) pathways." @default.
• W2085115221 created "2016-06-24" @default.
• W2085115221 creator A5003769106 @default.
• W2085115221 creator A5048218662 @default.
• W2085115221 creator A5051541306 @default.
• W2085115221 creator A5072360221 @default.
• W2085115221 creator A5081025860 @default.
• W2085115221 date "2004-02-01" @default.
• W2085115221 modified "2023-10-16" @default.
• W2085115221 title "Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor γ" @default.
• W2085115221 cites W1527321128 @default.
• W2085115221 cites W1598719623 @default.
• W2085115221 cites W1964228990 @default.
• W2085115221 cites W1964678619 @default.
• W2085115221 cites W1966368804 @default.
• W2085115221 cites W1968143168 @default.
• W2085115221 cites W1969150166 @default.
• W2085115221 cites W1969437387 @default.
• W2085115221 cites W1970834072 @default.
• W2085115221 cites W1973398468 @default.
• W2085115221 cites W1977945401 @default.
• W2085115221 cites W1980199287 @default.
• W2085115221 cites W1981209904 @default.
• W2085115221 cites W1984723113 @default.
• W2085115221 cites W1987430342 @default.
• W2085115221 cites W1990539073 @default.
• W2085115221 cites W1991865867 @default.
• W2085115221 cites W1996402807 @default.
• W2085115221 cites W1996741456 @default.
• W2085115221 cites W1998232267 @default.
• W2085115221 cites W1998997365 @default.
• W2085115221 cites W1999038608 @default.
• W2085115221 cites W1999461623 @default.
• W2085115221 cites W2011174531 @default.
• W2085115221 cites W2023520601 @default.
• W2085115221 cites W2026102591 @default.
• W2085115221 cites W2031694725 @default.
• W2085115221 cites W2040406921 @default.
• W2085115221 cites W2042928863 @default.
• W2085115221 cites W2043707891 @default.
• W2085115221 cites W2047741256 @default.
• W2085115221 cites W2050352100 @default.
• W2085115221 cites W2062163402 @default.
• W2085115221 cites W2065844116 @default.
• W2085115221 cites W2066092624 @default.
• W2085115221 cites W2072907462 @default.
• W2085115221 cites W2077012773 @default.
• W2085115221 cites W2079226013 @default.
• W2085115221 cites W2080939920 @default.
• W2085115221 cites W2087259247 @default.
• W2085115221 cites W2088404163 @default.
• W2085115221 cites W2092288709 @default.
• W2085115221 cites W2093467508 @default.
• W2085115221 cites W2097357124 @default.
• W2085115221 cites W2100372858 @default.
• W2085115221 cites W2102998952 @default.
• W2085115221 cites W2105286509 @default.
• W2085115221 cites W2109694492 @default.
• W2085115221 cites W2117567491 @default.
• W2085115221 cites W2117900168 @default.
• W2085115221 cites W2125471714 @default.
• W2085115221 cites W2131161059 @default.
• W2085115221 cites W2132056777 @default.
• W2085115221 cites W2133313889 @default.
• W2085115221 cites W2134979684 @default.
• W2085115221 cites W2145168681 @default.
• W2085115221 cites W2147620227 @default.
• W2085115221 cites W2150966393 @default.
• W2085115221 cites W2151113660 @default.
• W2085115221 cites W2164108689 @default.
• W2085115221 cites W2169041339 @default.
• W2085115221 cites W238860423 @default.
• W2085115221 cites W4293247451 @default.
• W2085115221 cites W4296981683 @default.
• W2085115221 doi "https://doi.org/10.1158/0008-5472.can-03-2556" @default.
• W2085115221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14871855" @default.
• W2085115221 hasPublicationYear "2004" @default.
• W2085115221 type Work @default.
• W2085115221 sameAs 2085115221 @default.
• W2085115221 citedByCount "58" @default.
• W2085115221 countsByYear W20851152212012 @default.
• W2085115221 countsByYear W20851152212014 @default.
• W2085115221 countsByYear W20851152212015 @default.
• W2085115221 countsByYear W20851152212017 @default.
• W2085115221 countsByYear W20851152212020 @default.
• W2085115221 countsByYear W20851152212021 @default.
• W2085115221 crossrefType "journal-article" @default.
• W2085115221 hasAuthorship W2085115221A5003769106 @default.
• W2085115221 hasAuthorship W2085115221A5048218662 @default.
• W2085115221 hasAuthorship W2085115221A5051541306 @default.
• W2085115221 hasAuthorship W2085115221A5072360221 @default.
• W2085115221 hasAuthorship W2085115221A5081025860 @default.
• W2085115221 hasConcept C121608353 @default.
• W2085115221 hasConcept C126322002 @default.
• W2085115221 hasConcept C127078168 @default.
• W2085115221 hasConcept C134018914 @default.
• W2085115221 hasConcept C170493617 @default.
• W2085115221 hasConcept C181199279 @default.

• next